{"id":57949,"date":"2026-02-25T16:55:36","date_gmt":"2026-02-25T08:55:36","guid":{"rendered":"https:\/\/flcube.com\/?p=57949"},"modified":"2026-02-25T16:55:37","modified_gmt":"2026-02-25T08:55:37","slug":"fda-approves-astrazenecas-calquence-plus-venetoclax-for-cll-sll-first-all-oral-fixed-duration-regimen","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57949","title":{"rendered":"FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL\/SLL \u2013 First All\u2011Oral Fixed\u2011Duration Regimen"},"content":{"rendered":"\n

AstraZeneca (AZ, NYSE:\u202fAZN<\/a>)<\/strong> announced that the U.S. Food and Drug Administration (FDA)<\/strong> has approved the combination of Calquence (acalabrutinib)<\/strong> and venetoclax<\/strong> for the treatment of adult patients with chronic lymphocytic leukemia (CLL)<\/strong> and small lymphocytic lymphoma (SLL)<\/strong>. The approval marks the first all\u2011oral, fixed\u2011duration treatment regimen<\/strong> approved for this indication, offering patients a time\u2011limited therapy option that minimizes long\u2011term side effects and resistance development.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>AstraZeneca (NYSE:\u202fAZN)<\/td><\/tr>
Products<\/strong><\/td>Calquence (acalabrutinib) + venetoclax<\/td><\/tr>
Regulatory Body<\/strong><\/td>U.S. Food and Drug Administration (FDA)<\/td><\/tr>
New Indication<\/strong><\/td>CLL and SLL in adult patients<\/td><\/tr>
Clinical Study<\/strong><\/td>Phase III AMPLIFY<\/td><\/tr>
Significance<\/strong><\/td>First all\u2011oral, fixed\u2011duration regimen approved for CLL\/SLL<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 AMPLIFY Phase III Study<\/h2>\n\n\n\n
Endpoint<\/th>Calquence + Venetoclax<\/th>Calquence + Venetoclax + Obinutuzumab<\/th>Chemoimmunotherapy (Standard of Care)<\/th><\/tr><\/thead>
3\u2011Year PFS Rate<\/strong><\/td>77%<\/strong><\/td>83%<\/strong><\/td>67%<\/td><\/tr>
Median PFS<\/strong><\/td>Not reached<\/td>Not reached<\/td>47.6 months<\/td><\/tr>
Risk Reduction (Progression\/Death)<\/strong><\/td>35%<\/strong><\/td>58%<\/strong><\/td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Treatment Regimen Advantages<\/h2>\n\n\n\n
Feature<\/th>Benefit<\/th><\/tr><\/thead>
All\u2011Oral Administration<\/strong><\/td>Eliminates infusion requirements; improves patient convenience<\/td><\/tr>
Fixed\u2011Duration<\/strong><\/td>Time\u2011limited therapy (vs. continuous BTK inhibition)<\/td><\/tr>
Side Effect Minimization<\/strong><\/td>Reduced long\u2011term toxicity exposure<\/td><\/tr>
Resistance Prevention<\/strong><\/td>Lower risk of clonal evolution and drug resistance<\/td><\/tr>
Compliance Improvement<\/strong><\/td>Defined treatment endpoint enhances adherence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Safety Profile<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Safety Consistency<\/strong><\/td>Calquence profile consistent with previous studies<\/td><\/tr>
New Safety Signals<\/strong><\/td>None identified<\/td><\/tr>
Tolerability<\/strong><\/td>Favorable vs. chemoimmunotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Global Regulatory Status<\/h2>\n\n\n\n
Region<\/th>Status<\/th><\/tr><\/thead>
European Union<\/strong><\/td>Approved<\/td><\/tr>
Canada<\/strong><\/td>Approved<\/td><\/tr>
United Kingdom<\/strong><\/td>Approved<\/td><\/tr>
United States<\/strong><\/td>Approved (Feb\u202f2026)<\/td><\/tr>
Additional Regions<\/strong><\/td>Under review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n